The Ministry of Health (MOH) invites healthcare professionals to access clinical evidence summaries which are being developed in response to emerging evidence on potential therapeutic options for COVID-19 on the MOH website at https://www.moh.gov.sg/covid-19/clinical-evidence-summaries.
1. As there is a lot of information on the internet which may not be accurate, MOH encourages healthcare professionals to refer to the evidence summaries to obtain the most updated information. As the situation is evolving rapidly, the clinical summaries will be updated regularly as new evidence emerges.
2. Four evidence summaries are currently uploaded on the MOH website:
- Should ibuprofen be used for COVID-19?; and
- Should ACE-inhibitors and Angiotensin-II-receptor blockers be stopped for COVID-19?
- Should favipiravir be used for COVID-19?
- Should protease inhibitors be used for COVID-19?
3. Six more evidence summaries will be uploaded this week on the following therapeutic options:
- Convalescent plasma [to be uploaded on 25 March 2020]
- Remdesivir [to be uploaded on 25 March 2020]
- Antimalarials (chloroquine and hydroxychloroquine) [to be uploaded on 25 March 2020]
- Interleukin-6 inhibitors (tocilizumab) [to be uploaded on 25 March 2020]
- Faviparivir [to be uploaded later this week]
- Protease inhibitors (lopinavir/ritonavir) [to be uploaded later this week]
4. If you have any enquiries/have a clinical topic that they would like ACE to review, they are welcome to email the Secretariat at MOH_DAC_Secretariat@moh.gov.sg.
